Journals / Turkish Journal of Hematology / 2021 / Cilt: 38 - Sayı: 4

A Rare Lymphoproliferative Disease: Castleman Disease

Nadir Bir Lenfoproliferatif Hastalık: Castleman Hastalığı

Pages
314–320
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper, recent information about Castleman disease, which is a rare disease, is summarized.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Castleman disease is a rare lymphoproliferative disease also known as angiofollicular lymph node hyperplasia.
📊
Key Findings & Data:Although the pathogenesis is not completely understood, the role of interleukin (IL)-6 in unicentric disease and the roles of IL-6 and human herpes virus-8 in multicentric disease are well defined.
💡
Conclusion & Impact:In this paper, recent information about Castleman disease, which is a rare disease, is summarized.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Castleman disease is a rare lymphoproliferative disease also known as angiofollicular lymph node hyperplasia. It is classified as hyaline vascular and plasmacytic variants histologically but characteristics of both types can coexist. Most unicentric cases of the disease are hyaline vascular while most multicentric cases are of the plasmacytic type. Although the pathogenesis is not completely understood, the role of interleukin (IL)-6 in unicentric disease and the roles of IL-6 and human herpes virus-8 in multicentric disease are well defined. Unicentric disease is typically localized and symptoms are minimal and treated locally. Multicentric disease is systemic and clinically characterized by generalized lymphadenopathy, splenomegaly, anemia, and systemic inflammatory symptoms. Systemic therapies are primarily given. Several malignant diseases including lymphomas, POEMS syndrome, follicular dendritic cell sarcomas, paraneoplastic pemphigus, Kaposi sarcoma, and amyloidosis can be associated with Castleman disease. In this paper, recent information about Castleman disease, which is a rare disease, is summarized.

Özet

Castleman hastalığı, anjiyofolliküler lenf nodu hiperplazisi olarak da bilinen nadir bir lenfoproliferatif hastalıktır. Histolojik olarak hiyalin vasküler ve plazmasitik varyant olarak sınıflandırılır ancak nadiren iki tipe ait özellikler bir arada bulunabilir. Unisentrik hastalığı olan olguların çoğu hiyalin vasküler, multisentrik hastalığı olan olguların çoğu ise plazma hücreli histolojik tipindedir. Patogenezi tam olarak anlaşılmamıştır fakat unisentrik hastalıkta interlökin (IL)-6’nın, multisentrik hastalıkta IL-6 ve human herpes virüs-8’in rolü iyi tanımlanmıştır. Unisentrik hastalık tipik olarak lokalizedir, semptomlar minimaldir ve tek başına lokal tedavi uygulanır. Multisentrik hastalık sistemik bir hastalıktır ve klinik olarak yaygın lenfadenopati, splenomegali, anemi ve sistemik inflamatuar semptomlarla karakterizedir. Başlıca sistemik tedaviler uygulanır. Lenfomalar, POEMS sendromu, folliküler dendritik hücreli sarkomlar, paraneoplastik pemphigus, Kaposi sarkomu, amiloidoz Castleman hastalığı ile ilişkili olabilir. Bu yazıda nadir bir hastalık olan Castleman hastalığı ile ilgili güncel bilgiler özetlenmiştir.

🔖

Cite This Article

Gündüz, E., Özdemir, N., Bakanay, Ş. M., Karakuş, S. (2022). A Rare Lymphoproliferative Disease: Castleman Disease. Turkish Journal of Hematology, Cilt: 38 - Sayı: 4, 314–320. https://ajindex.com/articles/606532

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Munshi N, Mehra M, van de Velde H, Desai A, Potluri R, Vermeulen J. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma 2015;56:1252-1260
  2. Cervantes CE, Correa R. Castleman disease: a rare condition with endocrine manifestations. Cureus 2015;7:e380
  3. Bonekamp D, Horton KM, Hruban RH, Fishman EK. Castleman disease: the great mimic. Radiographics 2011;31:1793-1807
  4. Jiang JP, Shen XF, Du JF, Guan WX. A retrospective study of 34 patients with unicentric and multicentric Castleman’s disease: experience from a single institution. Oncol Lett 2018;15:2407-2412
  5. Yu JY, Oh IJ, Kim KS, Kim YI, Lim SC, Kim YC, Choi YD, Kwon YS. Castleman’s disease presenting as a tracheal mass. Ann Thorac Surg 2014;97:1798-1800
  6. Ye B, Gao SG, Li W, Yang LH, Zhao SH, Ma K, Zhu XL, Liu XY, Sun KL. A retrospective study of unicentric and multicentric Castleman’s disease: a report of 52 patients. Med Oncol 2010;27:1171-1178
  7. Luo JM, Li S, Huang H, Cao J, Xu K, Bi YL, Feng RE, Huang C, Qin YZ, Xu ZJ, Xiao Y. Clinical spectrum of intrathoracic Castleman disease: a retrospective analysis of 48 cases in a single Chinese hospital. BMC Pulm Med 2015;15:34
  8. Kligerman SJ, Auerbach A, Franks TJ, Galvin JR. Castleman disease of the thorax: clinical, radiologic, and pathologic correlation: from the radiologic pathology archives. Radiographics 2016;36:1309-1332
  9. Cronin DMP, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009;16:236-246
  10. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d’Agay MF, Clauvel JP, Raphael M, Degos L, Sigaux F. Kaposi’s sarcomaassociated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 1995;86:1276-1280
  11. Slazat R, Munchi NC. Diagnosis of Castleman disease. Hematol Oncol Clin N Am 2018;32:53-64
  12. Koa B, Borja AJ, Aly M, Padmanabhan S, Tran J, Zhang V, Rojulpotel C, Pierson SK, Tamakloe MA, Khor JS, Werner TJ, Fajgenbaum DC, Alavi A, Revheim ME. Emerging role of 18F‑FDG PET/CT in Castleman disease: a review. Insights Imaging 2021;12:35-45
  13. Scott D, Cabral L, Harrington WJ Jr. Treatment of HIV-associated multicentric Castleman’s disease with oral etoposide. Am J Hematol 2001;66:148-150
  14. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998;128:657-662
  15. Fajgenbaum DC, Ul